Replies to post #71301 on Biotech Values

[DewDiligence]

VRUS – I guess that this kind of conditioned enrollment reflects the FDA's worry over safety and will slow the trial.

Agreed. A two-stage enrollment schedule would seem to be overkill at this stage in the development program. I presume that the kidney tox in monkeys played a role in the FDA’s mandate.